Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]Code Context
trigger_error($message, E_USER_DEPRECATED);
}
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.' $stackFrame = (int) 1 $trace = [ (int) 0 => [ 'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php', 'line' => (int) 2421, 'function' => 'deprecationWarning', 'args' => [ (int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.' ] ], (int) 1 => [ 'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php', 'line' => (int) 73, 'function' => 'offsetGet', 'class' => 'Cake\Http\ServerRequest', 'object' => object(Cake\Http\ServerRequest) {}, 'type' => '->', 'args' => [ (int) 0 => 'catslug' ] ], (int) 2 => [ 'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php', 'line' => (int) 610, 'function' => 'printArticle', 'class' => 'App\Controller\ArtileDetailController', 'object' => object(App\Controller\ArtileDetailController) {}, 'type' => '->', 'args' => [] ], (int) 3 => [ 'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php', 'line' => (int) 120, 'function' => 'invokeAction', 'class' => 'Cake\Controller\Controller', 'object' => object(App\Controller\ArtileDetailController) {}, 'type' => '->', 'args' => [] ], (int) 4 => [ 'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php', 'line' => (int) 94, 'function' => '_invoke', 'class' => 'Cake\Http\ActionDispatcher', 'object' => object(Cake\Http\ActionDispatcher) {}, 'type' => '->', 'args' => [ (int) 0 => object(App\Controller\ArtileDetailController) {} ] ], (int) 5 => [ 'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php', 'line' => (int) 235, 'function' => 'dispatch', 'class' => 'Cake\Http\ActionDispatcher', 'object' => object(Cake\Http\ActionDispatcher) {}, 'type' => '->', 'args' => [ (int) 0 => object(Cake\Http\ServerRequest) {}, (int) 1 => object(Cake\Http\Response) {} ] ], (int) 6 => [ 'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php', 'line' => (int) 65, 'function' => '__invoke', 'class' => 'Cake\Http\BaseApplication', 'object' => object(App\Application) {}, 'type' => '->', 'args' => [ (int) 0 => object(Cake\Http\ServerRequest) {}, (int) 1 => object(Cake\Http\Response) {}, (int) 2 => object(Cake\Http\Runner) {} ] ], (int) 7 => [ 'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php', 'line' => (int) 162, 'function' => '__invoke', 'class' => 'Cake\Http\Runner', 'object' => object(Cake\Http\Runner) {}, 'type' => '->', 'args' => [ (int) 0 => object(Cake\Http\ServerRequest) {}, (int) 1 => object(Cake\Http\Response) {} ] ], (int) 8 => [ 'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php', 'line' => (int) 65, 'function' => '__invoke', 'class' => 'Cake\Routing\Middleware\RoutingMiddleware', 'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {}, 'type' => '->', 'args' => [ (int) 0 => object(Cake\Http\ServerRequest) {}, (int) 1 => object(Cake\Http\Response) {}, (int) 2 => object(Cake\Http\Runner) {} ] ], (int) 9 => [ 'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php', 'line' => (int) 88, 'function' => '__invoke', 'class' => 'Cake\Http\Runner', 'object' => object(Cake\Http\Runner) {}, 'type' => '->', 'args' => [ (int) 0 => object(Cake\Http\ServerRequest) {}, (int) 1 => object(Cake\Http\Response) {} ] ], (int) 10 => [ 'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php', 'line' => (int) 65, 'function' => '__invoke', 'class' => 'Cake\Routing\Middleware\AssetMiddleware', 'object' => object(Cake\Routing\Middleware\AssetMiddleware) {}, 'type' => '->', 'args' => [ (int) 0 => object(Cake\Http\ServerRequest) {}, (int) 1 => object(Cake\Http\Response) {}, (int) 2 => object(Cake\Http\Runner) {} ] ], (int) 11 => [ 'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php', 'line' => (int) 96, 'function' => '__invoke', 'class' => 'Cake\Http\Runner', 'object' => object(Cake\Http\Runner) {}, 'type' => '->', 'args' => [ (int) 0 => object(Cake\Http\ServerRequest) {}, (int) 1 => object(Cake\Http\Response) {} ] ], (int) 12 => [ 'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php', 'line' => (int) 65, 'function' => '__invoke', 'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware', 'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {}, 'type' => '->', 'args' => [ (int) 0 => object(Cake\Http\ServerRequest) {}, (int) 1 => object(Cake\Http\Response) {}, (int) 2 => object(Cake\Http\Runner) {} ] ], (int) 13 => [ 'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php', 'line' => (int) 51, 'function' => '__invoke', 'class' => 'Cake\Http\Runner', 'object' => object(Cake\Http\Runner) {}, 'type' => '->', 'args' => [ (int) 0 => object(Cake\Http\ServerRequest) {}, (int) 1 => object(Cake\Http\Response) {} ] ], (int) 14 => [ 'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php', 'line' => (int) 98, 'function' => 'run', 'class' => 'Cake\Http\Runner', 'object' => object(Cake\Http\Runner) {}, 'type' => '->', 'args' => [ (int) 0 => object(Cake\Http\MiddlewareQueue) {}, (int) 1 => object(Cake\Http\ServerRequest) {}, (int) 2 => object(Cake\Http\Response) {} ] ], (int) 15 => [ 'file' => '/home/brlfuser/public_html/webroot/index.php', 'line' => (int) 39, 'function' => 'run', 'class' => 'Cake\Http\Server', 'object' => object(Cake\Http\Server) {}, 'type' => '->', 'args' => [] ] ] $frame = [ 'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php', 'line' => (int) 73, 'function' => 'offsetGet', 'class' => 'Cake\Http\ServerRequest', 'object' => object(Cake\Http\ServerRequest) { trustProxy => false [protected] params => [ [maximum depth reached] ] [protected] data => [[maximum depth reached]] [protected] query => [[maximum depth reached]] [protected] cookies => [[maximum depth reached]] [protected] _environment => [ [maximum depth reached] ] [protected] url => 'latest-news-updates/not-the-right-medicine-363/print' [protected] base => '' [protected] webroot => '/' [protected] here => '/latest-news-updates/not-the-right-medicine-363/print' [protected] trustedProxies => [[maximum depth reached]] [protected] _input => null [protected] _detectors => [ [maximum depth reached] ] [protected] _detectorCache => [ [maximum depth reached] ] [protected] stream => object(Zend\Diactoros\PhpInputStream) {} [protected] uri => object(Zend\Diactoros\Uri) {} [protected] session => object(Cake\Http\Session) {} [protected] attributes => [[maximum depth reached]] [protected] emulatedAttributes => [ [maximum depth reached] ] [protected] uploadedFiles => [[maximum depth reached]] [protected] protocol => null [protected] requestTarget => null [private] deprecatedProperties => [ [maximum depth reached] ] }, 'type' => '->', 'args' => [ (int) 0 => 'catslug' ] ]deprecationWarning - CORE/src/Core/functions.php, line 311 Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421 App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 73 Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610 Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120 Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94 Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235 Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65 Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162 Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65 Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88 Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65 Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96 Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65 Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51 Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98
Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]Code Context
trigger_error($message, E_USER_DEPRECATED);
}
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.' $stackFrame = (int) 1 $trace = [ (int) 0 => [ 'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php', 'line' => (int) 2421, 'function' => 'deprecationWarning', 'args' => [ (int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.' ] ], (int) 1 => [ 'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php', 'line' => (int) 74, 'function' => 'offsetGet', 'class' => 'Cake\Http\ServerRequest', 'object' => object(Cake\Http\ServerRequest) {}, 'type' => '->', 'args' => [ (int) 0 => 'artileslug' ] ], (int) 2 => [ 'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php', 'line' => (int) 610, 'function' => 'printArticle', 'class' => 'App\Controller\ArtileDetailController', 'object' => object(App\Controller\ArtileDetailController) {}, 'type' => '->', 'args' => [] ], (int) 3 => [ 'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php', 'line' => (int) 120, 'function' => 'invokeAction', 'class' => 'Cake\Controller\Controller', 'object' => object(App\Controller\ArtileDetailController) {}, 'type' => '->', 'args' => [] ], (int) 4 => [ 'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php', 'line' => (int) 94, 'function' => '_invoke', 'class' => 'Cake\Http\ActionDispatcher', 'object' => object(Cake\Http\ActionDispatcher) {}, 'type' => '->', 'args' => [ (int) 0 => object(App\Controller\ArtileDetailController) {} ] ], (int) 5 => [ 'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php', 'line' => (int) 235, 'function' => 'dispatch', 'class' => 'Cake\Http\ActionDispatcher', 'object' => object(Cake\Http\ActionDispatcher) {}, 'type' => '->', 'args' => [ (int) 0 => object(Cake\Http\ServerRequest) {}, (int) 1 => object(Cake\Http\Response) {} ] ], (int) 6 => [ 'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php', 'line' => (int) 65, 'function' => '__invoke', 'class' => 'Cake\Http\BaseApplication', 'object' => object(App\Application) {}, 'type' => '->', 'args' => [ (int) 0 => object(Cake\Http\ServerRequest) {}, (int) 1 => object(Cake\Http\Response) {}, (int) 2 => object(Cake\Http\Runner) {} ] ], (int) 7 => [ 'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php', 'line' => (int) 162, 'function' => '__invoke', 'class' => 'Cake\Http\Runner', 'object' => object(Cake\Http\Runner) {}, 'type' => '->', 'args' => [ (int) 0 => object(Cake\Http\ServerRequest) {}, (int) 1 => object(Cake\Http\Response) {} ] ], (int) 8 => [ 'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php', 'line' => (int) 65, 'function' => '__invoke', 'class' => 'Cake\Routing\Middleware\RoutingMiddleware', 'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {}, 'type' => '->', 'args' => [ (int) 0 => object(Cake\Http\ServerRequest) {}, (int) 1 => object(Cake\Http\Response) {}, (int) 2 => object(Cake\Http\Runner) {} ] ], (int) 9 => [ 'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php', 'line' => (int) 88, 'function' => '__invoke', 'class' => 'Cake\Http\Runner', 'object' => object(Cake\Http\Runner) {}, 'type' => '->', 'args' => [ (int) 0 => object(Cake\Http\ServerRequest) {}, (int) 1 => object(Cake\Http\Response) {} ] ], (int) 10 => [ 'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php', 'line' => (int) 65, 'function' => '__invoke', 'class' => 'Cake\Routing\Middleware\AssetMiddleware', 'object' => object(Cake\Routing\Middleware\AssetMiddleware) {}, 'type' => '->', 'args' => [ (int) 0 => object(Cake\Http\ServerRequest) {}, (int) 1 => object(Cake\Http\Response) {}, (int) 2 => object(Cake\Http\Runner) {} ] ], (int) 11 => [ 'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php', 'line' => (int) 96, 'function' => '__invoke', 'class' => 'Cake\Http\Runner', 'object' => object(Cake\Http\Runner) {}, 'type' => '->', 'args' => [ (int) 0 => object(Cake\Http\ServerRequest) {}, (int) 1 => object(Cake\Http\Response) {} ] ], (int) 12 => [ 'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php', 'line' => (int) 65, 'function' => '__invoke', 'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware', 'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {}, 'type' => '->', 'args' => [ (int) 0 => object(Cake\Http\ServerRequest) {}, (int) 1 => object(Cake\Http\Response) {}, (int) 2 => object(Cake\Http\Runner) {} ] ], (int) 13 => [ 'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php', 'line' => (int) 51, 'function' => '__invoke', 'class' => 'Cake\Http\Runner', 'object' => object(Cake\Http\Runner) {}, 'type' => '->', 'args' => [ (int) 0 => object(Cake\Http\ServerRequest) {}, (int) 1 => object(Cake\Http\Response) {} ] ], (int) 14 => [ 'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php', 'line' => (int) 98, 'function' => 'run', 'class' => 'Cake\Http\Runner', 'object' => object(Cake\Http\Runner) {}, 'type' => '->', 'args' => [ (int) 0 => object(Cake\Http\MiddlewareQueue) {}, (int) 1 => object(Cake\Http\ServerRequest) {}, (int) 2 => object(Cake\Http\Response) {} ] ], (int) 15 => [ 'file' => '/home/brlfuser/public_html/webroot/index.php', 'line' => (int) 39, 'function' => 'run', 'class' => 'Cake\Http\Server', 'object' => object(Cake\Http\Server) {}, 'type' => '->', 'args' => [] ] ] $frame = [ 'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php', 'line' => (int) 74, 'function' => 'offsetGet', 'class' => 'Cake\Http\ServerRequest', 'object' => object(Cake\Http\ServerRequest) { trustProxy => false [protected] params => [ [maximum depth reached] ] [protected] data => [[maximum depth reached]] [protected] query => [[maximum depth reached]] [protected] cookies => [[maximum depth reached]] [protected] _environment => [ [maximum depth reached] ] [protected] url => 'latest-news-updates/not-the-right-medicine-363/print' [protected] base => '' [protected] webroot => '/' [protected] here => '/latest-news-updates/not-the-right-medicine-363/print' [protected] trustedProxies => [[maximum depth reached]] [protected] _input => null [protected] _detectors => [ [maximum depth reached] ] [protected] _detectorCache => [ [maximum depth reached] ] [protected] stream => object(Zend\Diactoros\PhpInputStream) {} [protected] uri => object(Zend\Diactoros\Uri) {} [protected] session => object(Cake\Http\Session) {} [protected] attributes => [[maximum depth reached]] [protected] emulatedAttributes => [ [maximum depth reached] ] [protected] uploadedFiles => [[maximum depth reached]] [protected] protocol => null [protected] requestTarget => null [private] deprecatedProperties => [ [maximum depth reached] ] }, 'type' => '->', 'args' => [ (int) 0 => 'artileslug' ] ]deprecationWarning - CORE/src/Core/functions.php, line 311 Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421 App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 74 Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610 Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120 Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94 Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235 Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65 Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162 Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65 Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88 Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65 Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96 Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65 Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51 Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98
Warning (512): Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853 [CORE/src/Http/ResponseEmitter.php, line 48]Code Contextif (Configure::read('debug')) {
trigger_error($message, E_USER_WARNING);
} else {
$response = object(Cake\Http\Response) { 'status' => (int) 200, 'contentType' => 'text/html', 'headers' => [ 'Content-Type' => [ [maximum depth reached] ] ], 'file' => null, 'fileRange' => [], 'cookies' => object(Cake\Http\Cookie\CookieCollection) {}, 'cacheDirectives' => [], 'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd"> <html xmlns="http://www.w3.org/1999/xhtml"> <head> <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr6824c0b99a162-trace').style.display = (document.getElementById('cakeErr6824c0b99a162-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr6824c0b99a162-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr6824c0b99a162-code').style.display = (document.getElementById('cakeErr6824c0b99a162-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr6824c0b99a162-context').style.display = (document.getElementById('cakeErr6824c0b99a162-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr6824c0b99a162-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700"><</span><span style="color: #0000BB">head</span><span style="color: #007700">> </span></span></code> <span class="code-highlight"><code><span style="color: #000000"> <link rel="canonical" href="<span style="color: #0000BB"><?php </span><span style="color: #007700">echo </span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">); </span><span style="color: #0000BB">?><?php </span><span style="color: #007700">echo </span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?><?php </span><span style="color: #007700">echo </span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-></span><span style="color: #0000BB">category</span><span style="color: #007700">-></span><span style="color: #0000BB">slug</span><span style="color: #007700">; </span><span style="color: #0000BB">?></span>/<span style="color: #0000BB"><?php </span><span style="color: #007700">echo </span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-></span><span style="color: #0000BB">seo_url</span><span style="color: #007700">; </span><span style="color: #0000BB">?></span>.html"/> </span></code></span> <code><span style="color: #000000"><span style="color: #0000BB"> </span><span style="color: #007700"><</span><span style="color: #0000BB">meta http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type" </span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html; charset=utf-8"</span><span style="color: #007700">/> </span></span></code></pre><pre id="cakeErr6824c0b99a162-context" class="cake-context" style="display: none;">$viewFile = '/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp' $dataForView = [ 'article_current' => object(App\Model\Entity\Article) { 'id' => (int) 296, 'title' => 'Not the right medicine', 'subheading' => '', 'description' => '<p align="justify"> <font face="arial,helvetica,sans-serif" size="3"><em>Govt can help by raising public spending on healthcare</em></font> </p> <p align="justify"> <font face="arial,helvetica,sans-serif" size="3">The Indian Pharmaceutical Alliance, which represents a large section of the country&rsquo;s pharmaceutical companies, has taken the rather unusual step of asking the government to come to the aid of the industry, which has seen a string of foreign acquisitions of Indian players. None of these acquisitions is hostile. So, where does the government come in, particularly when there is no security issue at stake? It is also quite clear that some of these deals, like the most celebrated one of Ranbaxy going to its Japanese acquirer Daiichi Sankyo, have been very attractively priced. So, the industry has been doing quite well and managements have been able to exit at a premium. If the industry were in trouble and, therefore, needing government assistance, the scenario would have been different.</font> </p> <p align="justify"> <font face="arial,helvetica,sans-serif" size="3">Big global pharmaceutical firms seeking to buy into prominent Indian generic players is, in fact, a vindication of the Indian pharmaceutical story which began with the decision by Indira Gandhi to rein in the cost of medicines and allow process and not product patents. This policy environment and Indian expertise in chemistry led to the emergence of India as a prominent global player in generic drugs. As the patent pipeline of global firms has thinned out in recent years, they have realised the need to acquire a generics play and come shopping to India. Leading Indian players, for their part, have realised the importance of original drug discovery and firms like Ranbaxy and Dr Reddy&rsquo;s have since the early 90s concentrated heavily on it. Over the years, all important Indian players have seen the need to acquire a global footprint in terms of distribution and front offices and have gone shopping round the world. Things came to a head during the boom and easy money period earlier in this decade, leading to rather bold leveraged acquisitions. The subsequent financial crisis and global slowdown created a cash crisis, leading to sale of assets, as in the case of Wockhardt. How can the government protect the industry from excessive ambition? What is more, the Indian takeover initiative is still on with Sun Pharma locked in a hostile takeover battle for Israel&rsquo;s Taro. Hardly the moment for the government to say, we don&rsquo;t like takeovers.</font> </p> <p align="justify"> <font face="arial,helvetica,sans-serif" size="3">The Indian pharmaceutical industry certainly needs to do better, earn a higher margin which enables the best players to invest more in research to discover new molecules. Western firms do this by selling medicines generally at a high price and earning massively through their blockbuster patents. But Indian firms have excelled in high quality with low cost in the intensely competitive generics space. So, there is a chicken and egg dilemma here &mdash; you can&rsquo;t invest heavily in R&amp;D unless you have blockbusters, which you don&rsquo;t get unless you invest heavily in R&amp;D. There is a way out. What you cannot earn through high price, you can do partially by expanding volumes. Both public and private healthcare expenditure in India needs to go up enormously, thus giving Indian companies the necessary volumes. The government can help by sharply increasing public spending on healthcare. Plus, the Indian market is full of substandard medicines produced by small-scale units, which survive because of state government patronage and heavily discounted sales through chemists. The government can and should crack down on substandard drugs. This will mean higher sales for large, quality producers and so, more resources for research.</font> </p> <p align="justify"> <font face="arial,helvetica,sans-serif" size="3"><br /> &nbsp;<br /> &nbsp;<br /> &nbsp;</font> </p> ', 'credit_writer' => 'The Business Standard, 3 November, 2009, http://www.business-standard.com/india/news/notright-medicine/375100/', 'article_img' => '', 'article_img_thumb' => '', 'status' => (int) 1, 'show_on_home' => (int) 1, 'lang' => 'EN', 'category_id' => (int) 16, 'tag_keyword' => '', 'seo_url' => 'not-the-right-medicine-363', 'meta_title' => null, 'meta_keywords' => null, 'meta_description' => null, 'noindex' => (int) 0, 'publish_date' => object(Cake\I18n\FrozenDate) {}, 'most_visit_section_id' => null, 'article_big_img' => null, 'liveid' => (int) 363, 'created' => object(Cake\I18n\FrozenTime) {}, 'modified' => object(Cake\I18n\FrozenTime) {}, 'edate' => '', 'tags' => [[maximum depth reached]], 'category' => object(App\Model\Entity\Category) {}, '[new]' => false, '[accessible]' => [ [maximum depth reached] ], '[dirty]' => [[maximum depth reached]], '[original]' => [[maximum depth reached]], '[virtual]' => [[maximum depth reached]], '[hasErrors]' => false, '[errors]' => [[maximum depth reached]], '[invalid]' => [[maximum depth reached]], '[repository]' => 'Articles' }, 'articleid' => (int) 296, 'metaTitle' => 'LATEST NEWS UPDATES | Not the right medicine', 'metaKeywords' => null, 'metaDesc' => ' Govt can help by raising public spending on healthcare The Indian Pharmaceutical Alliance, which represents a large section of the country&rsquo;s pharmaceutical companies, has taken the rather unusual step of asking the government to come to the aid of the...', 'disp' => '<p align="justify"><font ><em>Govt can help by raising public spending on healthcare</em></font> </p><p align="justify"><font >The Indian Pharmaceutical Alliance, which represents a large section of the country&rsquo;s pharmaceutical companies, has taken the rather unusual step of asking the government to come to the aid of the industry, which has seen a string of foreign acquisitions of Indian players. None of these acquisitions is hostile. So, where does the government come in, particularly when there is no security issue at stake? It is also quite clear that some of these deals, like the most celebrated one of Ranbaxy going to its Japanese acquirer Daiichi Sankyo, have been very attractively priced. So, the industry has been doing quite well and managements have been able to exit at a premium. If the industry were in trouble and, therefore, needing government assistance, the scenario would have been different.</font> </p><p align="justify"><font >Big global pharmaceutical firms seeking to buy into prominent Indian generic players is, in fact, a vindication of the Indian pharmaceutical story which began with the decision by Indira Gandhi to rein in the cost of medicines and allow process and not product patents. This policy environment and Indian expertise in chemistry led to the emergence of India as a prominent global player in generic drugs. As the patent pipeline of global firms has thinned out in recent years, they have realised the need to acquire a generics play and come shopping to India. Leading Indian players, for their part, have realised the importance of original drug discovery and firms like Ranbaxy and Dr Reddy&rsquo;s have since the early 90s concentrated heavily on it. Over the years, all important Indian players have seen the need to acquire a global footprint in terms of distribution and front offices and have gone shopping round the world. Things came to a head during the boom and easy money period earlier in this decade, leading to rather bold leveraged acquisitions. The subsequent financial crisis and global slowdown created a cash crisis, leading to sale of assets, as in the case of Wockhardt. How can the government protect the industry from excessive ambition? What is more, the Indian takeover initiative is still on with Sun Pharma locked in a hostile takeover battle for Israel&rsquo;s Taro. Hardly the moment for the government to say, we don&rsquo;t like takeovers.</font> </p><p align="justify"><font >The Indian pharmaceutical industry certainly needs to do better, earn a higher margin which enables the best players to invest more in research to discover new molecules. Western firms do this by selling medicines generally at a high price and earning massively through their blockbuster patents. But Indian firms have excelled in high quality with low cost in the intensely competitive generics space. So, there is a chicken and egg dilemma here &mdash; you can&rsquo;t invest heavily in R&amp;D unless you have blockbusters, which you don&rsquo;t get unless you invest heavily in R&amp;D. There is a way out. What you cannot earn through high price, you can do partially by expanding volumes. Both public and private healthcare expenditure in India needs to go up enormously, thus giving Indian companies the necessary volumes. The government can help by sharply increasing public spending on healthcare. Plus, the Indian market is full of substandard medicines produced by small-scale units, which survive because of state government patronage and heavily discounted sales through chemists. The government can and should crack down on substandard drugs. This will mean higher sales for large, quality producers and so, more resources for research.</font> </p><p align="justify"><font ><br />&nbsp;<br />&nbsp;<br />&nbsp;</font> </p>', 'lang' => 'English', 'SITE_URL' => 'https://im4change.in/', 'site_title' => 'im4change', 'adminprix' => 'admin' ] $article_current = object(App\Model\Entity\Article) { 'id' => (int) 296, 'title' => 'Not the right medicine', 'subheading' => '', 'description' => '<p align="justify"> <font face="arial,helvetica,sans-serif" size="3"><em>Govt can help by raising public spending on healthcare</em></font> </p> <p align="justify"> <font face="arial,helvetica,sans-serif" size="3">The Indian Pharmaceutical Alliance, which represents a large section of the country&rsquo;s pharmaceutical companies, has taken the rather unusual step of asking the government to come to the aid of the industry, which has seen a string of foreign acquisitions of Indian players. None of these acquisitions is hostile. So, where does the government come in, particularly when there is no security issue at stake? It is also quite clear that some of these deals, like the most celebrated one of Ranbaxy going to its Japanese acquirer Daiichi Sankyo, have been very attractively priced. So, the industry has been doing quite well and managements have been able to exit at a premium. If the industry were in trouble and, therefore, needing government assistance, the scenario would have been different.</font> </p> <p align="justify"> <font face="arial,helvetica,sans-serif" size="3">Big global pharmaceutical firms seeking to buy into prominent Indian generic players is, in fact, a vindication of the Indian pharmaceutical story which began with the decision by Indira Gandhi to rein in the cost of medicines and allow process and not product patents. This policy environment and Indian expertise in chemistry led to the emergence of India as a prominent global player in generic drugs. As the patent pipeline of global firms has thinned out in recent years, they have realised the need to acquire a generics play and come shopping to India. Leading Indian players, for their part, have realised the importance of original drug discovery and firms like Ranbaxy and Dr Reddy&rsquo;s have since the early 90s concentrated heavily on it. Over the years, all important Indian players have seen the need to acquire a global footprint in terms of distribution and front offices and have gone shopping round the world. Things came to a head during the boom and easy money period earlier in this decade, leading to rather bold leveraged acquisitions. The subsequent financial crisis and global slowdown created a cash crisis, leading to sale of assets, as in the case of Wockhardt. How can the government protect the industry from excessive ambition? What is more, the Indian takeover initiative is still on with Sun Pharma locked in a hostile takeover battle for Israel&rsquo;s Taro. Hardly the moment for the government to say, we don&rsquo;t like takeovers.</font> </p> <p align="justify"> <font face="arial,helvetica,sans-serif" size="3">The Indian pharmaceutical industry certainly needs to do better, earn a higher margin which enables the best players to invest more in research to discover new molecules. Western firms do this by selling medicines generally at a high price and earning massively through their blockbuster patents. But Indian firms have excelled in high quality with low cost in the intensely competitive generics space. So, there is a chicken and egg dilemma here &mdash; you can&rsquo;t invest heavily in R&amp;D unless you have blockbusters, which you don&rsquo;t get unless you invest heavily in R&amp;D. There is a way out. What you cannot earn through high price, you can do partially by expanding volumes. Both public and private healthcare expenditure in India needs to go up enormously, thus giving Indian companies the necessary volumes. The government can help by sharply increasing public spending on healthcare. Plus, the Indian market is full of substandard medicines produced by small-scale units, which survive because of state government patronage and heavily discounted sales through chemists. The government can and should crack down on substandard drugs. This will mean higher sales for large, quality producers and so, more resources for research.</font> </p> <p align="justify"> <font face="arial,helvetica,sans-serif" size="3"><br /> &nbsp;<br /> &nbsp;<br /> &nbsp;</font> </p> ', 'credit_writer' => 'The Business Standard, 3 November, 2009, http://www.business-standard.com/india/news/notright-medicine/375100/', 'article_img' => '', 'article_img_thumb' => '', 'status' => (int) 1, 'show_on_home' => (int) 1, 'lang' => 'EN', 'category_id' => (int) 16, 'tag_keyword' => '', 'seo_url' => 'not-the-right-medicine-363', 'meta_title' => null, 'meta_keywords' => null, 'meta_description' => null, 'noindex' => (int) 0, 'publish_date' => object(Cake\I18n\FrozenDate) {}, 'most_visit_section_id' => null, 'article_big_img' => null, 'liveid' => (int) 363, 'created' => object(Cake\I18n\FrozenTime) {}, 'modified' => object(Cake\I18n\FrozenTime) {}, 'edate' => '', 'tags' => [], 'category' => object(App\Model\Entity\Category) {}, '[new]' => false, '[accessible]' => [ '*' => true, 'id' => false ], '[dirty]' => [], '[original]' => [], '[virtual]' => [], '[hasErrors]' => false, '[errors]' => [], '[invalid]' => [], '[repository]' => 'Articles' } $articleid = (int) 296 $metaTitle = 'LATEST NEWS UPDATES | Not the right medicine' $metaKeywords = null $metaDesc = ' Govt can help by raising public spending on healthcare The Indian Pharmaceutical Alliance, which represents a large section of the country&rsquo;s pharmaceutical companies, has taken the rather unusual step of asking the government to come to the aid of the...' $disp = '<p align="justify"><font ><em>Govt can help by raising public spending on healthcare</em></font> </p><p align="justify"><font >The Indian Pharmaceutical Alliance, which represents a large section of the country&rsquo;s pharmaceutical companies, has taken the rather unusual step of asking the government to come to the aid of the industry, which has seen a string of foreign acquisitions of Indian players. None of these acquisitions is hostile. So, where does the government come in, particularly when there is no security issue at stake? It is also quite clear that some of these deals, like the most celebrated one of Ranbaxy going to its Japanese acquirer Daiichi Sankyo, have been very attractively priced. So, the industry has been doing quite well and managements have been able to exit at a premium. If the industry were in trouble and, therefore, needing government assistance, the scenario would have been different.</font> </p><p align="justify"><font >Big global pharmaceutical firms seeking to buy into prominent Indian generic players is, in fact, a vindication of the Indian pharmaceutical story which began with the decision by Indira Gandhi to rein in the cost of medicines and allow process and not product patents. This policy environment and Indian expertise in chemistry led to the emergence of India as a prominent global player in generic drugs. As the patent pipeline of global firms has thinned out in recent years, they have realised the need to acquire a generics play and come shopping to India. Leading Indian players, for their part, have realised the importance of original drug discovery and firms like Ranbaxy and Dr Reddy&rsquo;s have since the early 90s concentrated heavily on it. Over the years, all important Indian players have seen the need to acquire a global footprint in terms of distribution and front offices and have gone shopping round the world. Things came to a head during the boom and easy money period earlier in this decade, leading to rather bold leveraged acquisitions. The subsequent financial crisis and global slowdown created a cash crisis, leading to sale of assets, as in the case of Wockhardt. How can the government protect the industry from excessive ambition? What is more, the Indian takeover initiative is still on with Sun Pharma locked in a hostile takeover battle for Israel&rsquo;s Taro. Hardly the moment for the government to say, we don&rsquo;t like takeovers.</font> </p><p align="justify"><font >The Indian pharmaceutical industry certainly needs to do better, earn a higher margin which enables the best players to invest more in research to discover new molecules. Western firms do this by selling medicines generally at a high price and earning massively through their blockbuster patents. But Indian firms have excelled in high quality with low cost in the intensely competitive generics space. So, there is a chicken and egg dilemma here &mdash; you can&rsquo;t invest heavily in R&amp;D unless you have blockbusters, which you don&rsquo;t get unless you invest heavily in R&amp;D. There is a way out. What you cannot earn through high price, you can do partially by expanding volumes. Both public and private healthcare expenditure in India needs to go up enormously, thus giving Indian companies the necessary volumes. The government can help by sharply increasing public spending on healthcare. Plus, the Indian market is full of substandard medicines produced by small-scale units, which survive because of state government patronage and heavily discounted sales through chemists. The government can and should crack down on substandard drugs. This will mean higher sales for large, quality producers and so, more resources for research.</font> </p><p align="justify"><font ><br />&nbsp;<br />&nbsp;<br />&nbsp;</font> </p>' $lang = 'English' $SITE_URL = 'https://im4change.in/' $site_title = 'im4change' $adminprix = 'admin'</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8 Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413 Cake\View\View::_render() - CORE/src/View/View.php, line 1374 Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927 Cake\View\View::render() - CORE/src/View/View.php, line 885 Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791 Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126 Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94 Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235 Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65 Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162 Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65 Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88 Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65 Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96 Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65 Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/not-the-right-medicine-363.html"/> <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/> <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css" media="all"/> <title>LATEST NEWS UPDATES | Not the right medicine | Im4change.org</title> <meta name="description" content=" Govt can help by raising public spending on healthcare The Indian Pharmaceutical Alliance, which represents a large section of the country’s pharmaceutical companies, has taken the rather unusual step of asking the government to come to the aid of the..."/> <script src="https://im4change.in/js/jquery-1.10.2.js"></script> <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script> <script language="javascript" type="text/javascript"> $(document).ready(function () { var img = $("img")[0]; // Get my img elem var pic_real_width, pic_real_height; $("<img/>") // Make in memory copy of image to avoid css issues .attr("src", $(img).attr("src")) .load(function () { pic_real_width = this.width; // Note: $(this).width() will not pic_real_height = this.height; // work for in memory images. }); }); </script> <style type="text/css"> @media screen { div.divFooter { display: block; } } @media print { .printbutton { display: none !important; } } </style> </head> <body> <table cellpadding="0" cellspacing="0" border="0" width="98%" align="center"> <tr> <td class="top_bg"> <div class="divFooter"> <img src="https://im4change.in/images/logo1.jpg" height="59" border="0" alt="Resource centre on India's rural distress" style="padding-top:14px;"/> </div> </td> </tr> <tr> <td id="topspace"> </td> </tr> <tr id="topspace"> <td> </td> </tr> <tr> <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton"> <form><input type="button" value=" Print this page " onclick="window.print();return false;"/></form> </td> </tr> <tr> <td width="100%"> <h1 class="news_headlines" style="font-style:normal"> <strong>Not the right medicine</strong></h1> </td> </tr> <tr> <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3"> <p align="justify"><font ><em>Govt can help by raising public spending on healthcare</em></font> </p><p align="justify"><font >The Indian Pharmaceutical Alliance, which represents a large section of the country’s pharmaceutical companies, has taken the rather unusual step of asking the government to come to the aid of the industry, which has seen a string of foreign acquisitions of Indian players. None of these acquisitions is hostile. So, where does the government come in, particularly when there is no security issue at stake? It is also quite clear that some of these deals, like the most celebrated one of Ranbaxy going to its Japanese acquirer Daiichi Sankyo, have been very attractively priced. So, the industry has been doing quite well and managements have been able to exit at a premium. If the industry were in trouble and, therefore, needing government assistance, the scenario would have been different.</font> </p><p align="justify"><font >Big global pharmaceutical firms seeking to buy into prominent Indian generic players is, in fact, a vindication of the Indian pharmaceutical story which began with the decision by Indira Gandhi to rein in the cost of medicines and allow process and not product patents. This policy environment and Indian expertise in chemistry led to the emergence of India as a prominent global player in generic drugs. As the patent pipeline of global firms has thinned out in recent years, they have realised the need to acquire a generics play and come shopping to India. Leading Indian players, for their part, have realised the importance of original drug discovery and firms like Ranbaxy and Dr Reddy’s have since the early 90s concentrated heavily on it. Over the years, all important Indian players have seen the need to acquire a global footprint in terms of distribution and front offices and have gone shopping round the world. Things came to a head during the boom and easy money period earlier in this decade, leading to rather bold leveraged acquisitions. The subsequent financial crisis and global slowdown created a cash crisis, leading to sale of assets, as in the case of Wockhardt. How can the government protect the industry from excessive ambition? What is more, the Indian takeover initiative is still on with Sun Pharma locked in a hostile takeover battle for Israel’s Taro. Hardly the moment for the government to say, we don’t like takeovers.</font> </p><p align="justify"><font >The Indian pharmaceutical industry certainly needs to do better, earn a higher margin which enables the best players to invest more in research to discover new molecules. Western firms do this by selling medicines generally at a high price and earning massively through their blockbuster patents. But Indian firms have excelled in high quality with low cost in the intensely competitive generics space. So, there is a chicken and egg dilemma here — you can’t invest heavily in R&D unless you have blockbusters, which you don’t get unless you invest heavily in R&D. There is a way out. What you cannot earn through high price, you can do partially by expanding volumes. Both public and private healthcare expenditure in India needs to go up enormously, thus giving Indian companies the necessary volumes. The government can help by sharply increasing public spending on healthcare. Plus, the Indian market is full of substandard medicines produced by small-scale units, which survive because of state government patronage and heavily discounted sales through chemists. The government can and should crack down on substandard drugs. This will mean higher sales for large, quality producers and so, more resources for research.</font> </p><p align="justify"><font ><br /> <br /> <br /> </font> </p> </font> </td> </tr> <tr> <td> </td> </tr> <tr> <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;"> <form><input type="button" value=" Print this page " onclick="window.print();return false;"/></form> </td> </tr> </table></body> </html>' } $maxBufferLength = (int) 8192 $file = '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php' $line = (int) 853 $message = 'Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853'Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 48 Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141 [main] - ROOT/webroot/index.php, line 39
Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 148]Code Context$response->getStatusCode(),
($reasonPhrase ? ' ' . $reasonPhrase : '')
));
$response = object(Cake\Http\Response) { 'status' => (int) 200, 'contentType' => 'text/html', 'headers' => [ 'Content-Type' => [ [maximum depth reached] ] ], 'file' => null, 'fileRange' => [], 'cookies' => object(Cake\Http\Cookie\CookieCollection) {}, 'cacheDirectives' => [], 'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd"> <html xmlns="http://www.w3.org/1999/xhtml"> <head> <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr6824c0b99a162-trace').style.display = (document.getElementById('cakeErr6824c0b99a162-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr6824c0b99a162-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr6824c0b99a162-code').style.display = (document.getElementById('cakeErr6824c0b99a162-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr6824c0b99a162-context').style.display = (document.getElementById('cakeErr6824c0b99a162-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr6824c0b99a162-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700"><</span><span style="color: #0000BB">head</span><span style="color: #007700">> </span></span></code> <span class="code-highlight"><code><span style="color: #000000"> <link rel="canonical" href="<span style="color: #0000BB"><?php </span><span style="color: #007700">echo </span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">); </span><span style="color: #0000BB">?><?php </span><span style="color: #007700">echo </span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?><?php </span><span style="color: #007700">echo </span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-></span><span style="color: #0000BB">category</span><span style="color: #007700">-></span><span style="color: #0000BB">slug</span><span style="color: #007700">; </span><span style="color: #0000BB">?></span>/<span style="color: #0000BB"><?php </span><span style="color: #007700">echo </span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-></span><span style="color: #0000BB">seo_url</span><span style="color: #007700">; </span><span style="color: #0000BB">?></span>.html"/> </span></code></span> <code><span style="color: #000000"><span style="color: #0000BB"> </span><span style="color: #007700"><</span><span style="color: #0000BB">meta http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type" </span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html; charset=utf-8"</span><span style="color: #007700">/> </span></span></code></pre><pre id="cakeErr6824c0b99a162-context" class="cake-context" style="display: none;">$viewFile = '/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp' $dataForView = [ 'article_current' => object(App\Model\Entity\Article) { 'id' => (int) 296, 'title' => 'Not the right medicine', 'subheading' => '', 'description' => '<p align="justify"> <font face="arial,helvetica,sans-serif" size="3"><em>Govt can help by raising public spending on healthcare</em></font> </p> <p align="justify"> <font face="arial,helvetica,sans-serif" size="3">The Indian Pharmaceutical Alliance, which represents a large section of the country&rsquo;s pharmaceutical companies, has taken the rather unusual step of asking the government to come to the aid of the industry, which has seen a string of foreign acquisitions of Indian players. None of these acquisitions is hostile. So, where does the government come in, particularly when there is no security issue at stake? It is also quite clear that some of these deals, like the most celebrated one of Ranbaxy going to its Japanese acquirer Daiichi Sankyo, have been very attractively priced. So, the industry has been doing quite well and managements have been able to exit at a premium. If the industry were in trouble and, therefore, needing government assistance, the scenario would have been different.</font> </p> <p align="justify"> <font face="arial,helvetica,sans-serif" size="3">Big global pharmaceutical firms seeking to buy into prominent Indian generic players is, in fact, a vindication of the Indian pharmaceutical story which began with the decision by Indira Gandhi to rein in the cost of medicines and allow process and not product patents. This policy environment and Indian expertise in chemistry led to the emergence of India as a prominent global player in generic drugs. As the patent pipeline of global firms has thinned out in recent years, they have realised the need to acquire a generics play and come shopping to India. Leading Indian players, for their part, have realised the importance of original drug discovery and firms like Ranbaxy and Dr Reddy&rsquo;s have since the early 90s concentrated heavily on it. Over the years, all important Indian players have seen the need to acquire a global footprint in terms of distribution and front offices and have gone shopping round the world. Things came to a head during the boom and easy money period earlier in this decade, leading to rather bold leveraged acquisitions. The subsequent financial crisis and global slowdown created a cash crisis, leading to sale of assets, as in the case of Wockhardt. How can the government protect the industry from excessive ambition? What is more, the Indian takeover initiative is still on with Sun Pharma locked in a hostile takeover battle for Israel&rsquo;s Taro. Hardly the moment for the government to say, we don&rsquo;t like takeovers.</font> </p> <p align="justify"> <font face="arial,helvetica,sans-serif" size="3">The Indian pharmaceutical industry certainly needs to do better, earn a higher margin which enables the best players to invest more in research to discover new molecules. Western firms do this by selling medicines generally at a high price and earning massively through their blockbuster patents. But Indian firms have excelled in high quality with low cost in the intensely competitive generics space. So, there is a chicken and egg dilemma here &mdash; you can&rsquo;t invest heavily in R&amp;D unless you have blockbusters, which you don&rsquo;t get unless you invest heavily in R&amp;D. There is a way out. What you cannot earn through high price, you can do partially by expanding volumes. Both public and private healthcare expenditure in India needs to go up enormously, thus giving Indian companies the necessary volumes. The government can help by sharply increasing public spending on healthcare. Plus, the Indian market is full of substandard medicines produced by small-scale units, which survive because of state government patronage and heavily discounted sales through chemists. The government can and should crack down on substandard drugs. This will mean higher sales for large, quality producers and so, more resources for research.</font> </p> <p align="justify"> <font face="arial,helvetica,sans-serif" size="3"><br /> &nbsp;<br /> &nbsp;<br /> &nbsp;</font> </p> ', 'credit_writer' => 'The Business Standard, 3 November, 2009, http://www.business-standard.com/india/news/notright-medicine/375100/', 'article_img' => '', 'article_img_thumb' => '', 'status' => (int) 1, 'show_on_home' => (int) 1, 'lang' => 'EN', 'category_id' => (int) 16, 'tag_keyword' => '', 'seo_url' => 'not-the-right-medicine-363', 'meta_title' => null, 'meta_keywords' => null, 'meta_description' => null, 'noindex' => (int) 0, 'publish_date' => object(Cake\I18n\FrozenDate) {}, 'most_visit_section_id' => null, 'article_big_img' => null, 'liveid' => (int) 363, 'created' => object(Cake\I18n\FrozenTime) {}, 'modified' => object(Cake\I18n\FrozenTime) {}, 'edate' => '', 'tags' => [[maximum depth reached]], 'category' => object(App\Model\Entity\Category) {}, '[new]' => false, '[accessible]' => [ [maximum depth reached] ], '[dirty]' => [[maximum depth reached]], '[original]' => [[maximum depth reached]], '[virtual]' => [[maximum depth reached]], '[hasErrors]' => false, '[errors]' => [[maximum depth reached]], '[invalid]' => [[maximum depth reached]], '[repository]' => 'Articles' }, 'articleid' => (int) 296, 'metaTitle' => 'LATEST NEWS UPDATES | Not the right medicine', 'metaKeywords' => null, 'metaDesc' => ' Govt can help by raising public spending on healthcare The Indian Pharmaceutical Alliance, which represents a large section of the country&rsquo;s pharmaceutical companies, has taken the rather unusual step of asking the government to come to the aid of the...', 'disp' => '<p align="justify"><font ><em>Govt can help by raising public spending on healthcare</em></font> </p><p align="justify"><font >The Indian Pharmaceutical Alliance, which represents a large section of the country&rsquo;s pharmaceutical companies, has taken the rather unusual step of asking the government to come to the aid of the industry, which has seen a string of foreign acquisitions of Indian players. None of these acquisitions is hostile. So, where does the government come in, particularly when there is no security issue at stake? It is also quite clear that some of these deals, like the most celebrated one of Ranbaxy going to its Japanese acquirer Daiichi Sankyo, have been very attractively priced. So, the industry has been doing quite well and managements have been able to exit at a premium. If the industry were in trouble and, therefore, needing government assistance, the scenario would have been different.</font> </p><p align="justify"><font >Big global pharmaceutical firms seeking to buy into prominent Indian generic players is, in fact, a vindication of the Indian pharmaceutical story which began with the decision by Indira Gandhi to rein in the cost of medicines and allow process and not product patents. This policy environment and Indian expertise in chemistry led to the emergence of India as a prominent global player in generic drugs. As the patent pipeline of global firms has thinned out in recent years, they have realised the need to acquire a generics play and come shopping to India. Leading Indian players, for their part, have realised the importance of original drug discovery and firms like Ranbaxy and Dr Reddy&rsquo;s have since the early 90s concentrated heavily on it. Over the years, all important Indian players have seen the need to acquire a global footprint in terms of distribution and front offices and have gone shopping round the world. Things came to a head during the boom and easy money period earlier in this decade, leading to rather bold leveraged acquisitions. The subsequent financial crisis and global slowdown created a cash crisis, leading to sale of assets, as in the case of Wockhardt. How can the government protect the industry from excessive ambition? What is more, the Indian takeover initiative is still on with Sun Pharma locked in a hostile takeover battle for Israel&rsquo;s Taro. Hardly the moment for the government to say, we don&rsquo;t like takeovers.</font> </p><p align="justify"><font >The Indian pharmaceutical industry certainly needs to do better, earn a higher margin which enables the best players to invest more in research to discover new molecules. Western firms do this by selling medicines generally at a high price and earning massively through their blockbuster patents. But Indian firms have excelled in high quality with low cost in the intensely competitive generics space. So, there is a chicken and egg dilemma here &mdash; you can&rsquo;t invest heavily in R&amp;D unless you have blockbusters, which you don&rsquo;t get unless you invest heavily in R&amp;D. There is a way out. What you cannot earn through high price, you can do partially by expanding volumes. Both public and private healthcare expenditure in India needs to go up enormously, thus giving Indian companies the necessary volumes. The government can help by sharply increasing public spending on healthcare. Plus, the Indian market is full of substandard medicines produced by small-scale units, which survive because of state government patronage and heavily discounted sales through chemists. The government can and should crack down on substandard drugs. This will mean higher sales for large, quality producers and so, more resources for research.</font> </p><p align="justify"><font ><br />&nbsp;<br />&nbsp;<br />&nbsp;</font> </p>', 'lang' => 'English', 'SITE_URL' => 'https://im4change.in/', 'site_title' => 'im4change', 'adminprix' => 'admin' ] $article_current = object(App\Model\Entity\Article) { 'id' => (int) 296, 'title' => 'Not the right medicine', 'subheading' => '', 'description' => '<p align="justify"> <font face="arial,helvetica,sans-serif" size="3"><em>Govt can help by raising public spending on healthcare</em></font> </p> <p align="justify"> <font face="arial,helvetica,sans-serif" size="3">The Indian Pharmaceutical Alliance, which represents a large section of the country&rsquo;s pharmaceutical companies, has taken the rather unusual step of asking the government to come to the aid of the industry, which has seen a string of foreign acquisitions of Indian players. None of these acquisitions is hostile. So, where does the government come in, particularly when there is no security issue at stake? It is also quite clear that some of these deals, like the most celebrated one of Ranbaxy going to its Japanese acquirer Daiichi Sankyo, have been very attractively priced. So, the industry has been doing quite well and managements have been able to exit at a premium. If the industry were in trouble and, therefore, needing government assistance, the scenario would have been different.</font> </p> <p align="justify"> <font face="arial,helvetica,sans-serif" size="3">Big global pharmaceutical firms seeking to buy into prominent Indian generic players is, in fact, a vindication of the Indian pharmaceutical story which began with the decision by Indira Gandhi to rein in the cost of medicines and allow process and not product patents. This policy environment and Indian expertise in chemistry led to the emergence of India as a prominent global player in generic drugs. As the patent pipeline of global firms has thinned out in recent years, they have realised the need to acquire a generics play and come shopping to India. Leading Indian players, for their part, have realised the importance of original drug discovery and firms like Ranbaxy and Dr Reddy&rsquo;s have since the early 90s concentrated heavily on it. Over the years, all important Indian players have seen the need to acquire a global footprint in terms of distribution and front offices and have gone shopping round the world. Things came to a head during the boom and easy money period earlier in this decade, leading to rather bold leveraged acquisitions. The subsequent financial crisis and global slowdown created a cash crisis, leading to sale of assets, as in the case of Wockhardt. How can the government protect the industry from excessive ambition? What is more, the Indian takeover initiative is still on with Sun Pharma locked in a hostile takeover battle for Israel&rsquo;s Taro. Hardly the moment for the government to say, we don&rsquo;t like takeovers.</font> </p> <p align="justify"> <font face="arial,helvetica,sans-serif" size="3">The Indian pharmaceutical industry certainly needs to do better, earn a higher margin which enables the best players to invest more in research to discover new molecules. Western firms do this by selling medicines generally at a high price and earning massively through their blockbuster patents. But Indian firms have excelled in high quality with low cost in the intensely competitive generics space. So, there is a chicken and egg dilemma here &mdash; you can&rsquo;t invest heavily in R&amp;D unless you have blockbusters, which you don&rsquo;t get unless you invest heavily in R&amp;D. There is a way out. What you cannot earn through high price, you can do partially by expanding volumes. Both public and private healthcare expenditure in India needs to go up enormously, thus giving Indian companies the necessary volumes. The government can help by sharply increasing public spending on healthcare. Plus, the Indian market is full of substandard medicines produced by small-scale units, which survive because of state government patronage and heavily discounted sales through chemists. The government can and should crack down on substandard drugs. This will mean higher sales for large, quality producers and so, more resources for research.</font> </p> <p align="justify"> <font face="arial,helvetica,sans-serif" size="3"><br /> &nbsp;<br /> &nbsp;<br /> &nbsp;</font> </p> ', 'credit_writer' => 'The Business Standard, 3 November, 2009, http://www.business-standard.com/india/news/notright-medicine/375100/', 'article_img' => '', 'article_img_thumb' => '', 'status' => (int) 1, 'show_on_home' => (int) 1, 'lang' => 'EN', 'category_id' => (int) 16, 'tag_keyword' => '', 'seo_url' => 'not-the-right-medicine-363', 'meta_title' => null, 'meta_keywords' => null, 'meta_description' => null, 'noindex' => (int) 0, 'publish_date' => object(Cake\I18n\FrozenDate) {}, 'most_visit_section_id' => null, 'article_big_img' => null, 'liveid' => (int) 363, 'created' => object(Cake\I18n\FrozenTime) {}, 'modified' => object(Cake\I18n\FrozenTime) {}, 'edate' => '', 'tags' => [], 'category' => object(App\Model\Entity\Category) {}, '[new]' => false, '[accessible]' => [ '*' => true, 'id' => false ], '[dirty]' => [], '[original]' => [], '[virtual]' => [], '[hasErrors]' => false, '[errors]' => [], '[invalid]' => [], '[repository]' => 'Articles' } $articleid = (int) 296 $metaTitle = 'LATEST NEWS UPDATES | Not the right medicine' $metaKeywords = null $metaDesc = ' Govt can help by raising public spending on healthcare The Indian Pharmaceutical Alliance, which represents a large section of the country&rsquo;s pharmaceutical companies, has taken the rather unusual step of asking the government to come to the aid of the...' $disp = '<p align="justify"><font ><em>Govt can help by raising public spending on healthcare</em></font> </p><p align="justify"><font >The Indian Pharmaceutical Alliance, which represents a large section of the country&rsquo;s pharmaceutical companies, has taken the rather unusual step of asking the government to come to the aid of the industry, which has seen a string of foreign acquisitions of Indian players. None of these acquisitions is hostile. So, where does the government come in, particularly when there is no security issue at stake? It is also quite clear that some of these deals, like the most celebrated one of Ranbaxy going to its Japanese acquirer Daiichi Sankyo, have been very attractively priced. So, the industry has been doing quite well and managements have been able to exit at a premium. If the industry were in trouble and, therefore, needing government assistance, the scenario would have been different.</font> </p><p align="justify"><font >Big global pharmaceutical firms seeking to buy into prominent Indian generic players is, in fact, a vindication of the Indian pharmaceutical story which began with the decision by Indira Gandhi to rein in the cost of medicines and allow process and not product patents. This policy environment and Indian expertise in chemistry led to the emergence of India as a prominent global player in generic drugs. As the patent pipeline of global firms has thinned out in recent years, they have realised the need to acquire a generics play and come shopping to India. Leading Indian players, for their part, have realised the importance of original drug discovery and firms like Ranbaxy and Dr Reddy&rsquo;s have since the early 90s concentrated heavily on it. Over the years, all important Indian players have seen the need to acquire a global footprint in terms of distribution and front offices and have gone shopping round the world. Things came to a head during the boom and easy money period earlier in this decade, leading to rather bold leveraged acquisitions. The subsequent financial crisis and global slowdown created a cash crisis, leading to sale of assets, as in the case of Wockhardt. How can the government protect the industry from excessive ambition? What is more, the Indian takeover initiative is still on with Sun Pharma locked in a hostile takeover battle for Israel&rsquo;s Taro. Hardly the moment for the government to say, we don&rsquo;t like takeovers.</font> </p><p align="justify"><font >The Indian pharmaceutical industry certainly needs to do better, earn a higher margin which enables the best players to invest more in research to discover new molecules. Western firms do this by selling medicines generally at a high price and earning massively through their blockbuster patents. But Indian firms have excelled in high quality with low cost in the intensely competitive generics space. So, there is a chicken and egg dilemma here &mdash; you can&rsquo;t invest heavily in R&amp;D unless you have blockbusters, which you don&rsquo;t get unless you invest heavily in R&amp;D. There is a way out. What you cannot earn through high price, you can do partially by expanding volumes. Both public and private healthcare expenditure in India needs to go up enormously, thus giving Indian companies the necessary volumes. The government can help by sharply increasing public spending on healthcare. Plus, the Indian market is full of substandard medicines produced by small-scale units, which survive because of state government patronage and heavily discounted sales through chemists. The government can and should crack down on substandard drugs. This will mean higher sales for large, quality producers and so, more resources for research.</font> </p><p align="justify"><font ><br />&nbsp;<br />&nbsp;<br />&nbsp;</font> </p>' $lang = 'English' $SITE_URL = 'https://im4change.in/' $site_title = 'im4change' $adminprix = 'admin'</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8 Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413 Cake\View\View::_render() - CORE/src/View/View.php, line 1374 Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927 Cake\View\View::render() - CORE/src/View/View.php, line 885 Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791 Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126 Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94 Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235 Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65 Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162 Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65 Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88 Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65 Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96 Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65 Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/not-the-right-medicine-363.html"/> <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/> <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css" media="all"/> <title>LATEST NEWS UPDATES | Not the right medicine | Im4change.org</title> <meta name="description" content=" Govt can help by raising public spending on healthcare The Indian Pharmaceutical Alliance, which represents a large section of the country’s pharmaceutical companies, has taken the rather unusual step of asking the government to come to the aid of the..."/> <script src="https://im4change.in/js/jquery-1.10.2.js"></script> <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script> <script language="javascript" type="text/javascript"> $(document).ready(function () { var img = $("img")[0]; // Get my img elem var pic_real_width, pic_real_height; $("<img/>") // Make in memory copy of image to avoid css issues .attr("src", $(img).attr("src")) .load(function () { pic_real_width = this.width; // Note: $(this).width() will not pic_real_height = this.height; // work for in memory images. }); }); </script> <style type="text/css"> @media screen { div.divFooter { display: block; } } @media print { .printbutton { display: none !important; } } </style> </head> <body> <table cellpadding="0" cellspacing="0" border="0" width="98%" align="center"> <tr> <td class="top_bg"> <div class="divFooter"> <img src="https://im4change.in/images/logo1.jpg" height="59" border="0" alt="Resource centre on India's rural distress" style="padding-top:14px;"/> </div> </td> </tr> <tr> <td id="topspace"> </td> </tr> <tr id="topspace"> <td> </td> </tr> <tr> <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton"> <form><input type="button" value=" Print this page " onclick="window.print();return false;"/></form> </td> </tr> <tr> <td width="100%"> <h1 class="news_headlines" style="font-style:normal"> <strong>Not the right medicine</strong></h1> </td> </tr> <tr> <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3"> <p align="justify"><font ><em>Govt can help by raising public spending on healthcare</em></font> </p><p align="justify"><font >The Indian Pharmaceutical Alliance, which represents a large section of the country’s pharmaceutical companies, has taken the rather unusual step of asking the government to come to the aid of the industry, which has seen a string of foreign acquisitions of Indian players. None of these acquisitions is hostile. So, where does the government come in, particularly when there is no security issue at stake? It is also quite clear that some of these deals, like the most celebrated one of Ranbaxy going to its Japanese acquirer Daiichi Sankyo, have been very attractively priced. So, the industry has been doing quite well and managements have been able to exit at a premium. If the industry were in trouble and, therefore, needing government assistance, the scenario would have been different.</font> </p><p align="justify"><font >Big global pharmaceutical firms seeking to buy into prominent Indian generic players is, in fact, a vindication of the Indian pharmaceutical story which began with the decision by Indira Gandhi to rein in the cost of medicines and allow process and not product patents. This policy environment and Indian expertise in chemistry led to the emergence of India as a prominent global player in generic drugs. As the patent pipeline of global firms has thinned out in recent years, they have realised the need to acquire a generics play and come shopping to India. Leading Indian players, for their part, have realised the importance of original drug discovery and firms like Ranbaxy and Dr Reddy’s have since the early 90s concentrated heavily on it. Over the years, all important Indian players have seen the need to acquire a global footprint in terms of distribution and front offices and have gone shopping round the world. Things came to a head during the boom and easy money period earlier in this decade, leading to rather bold leveraged acquisitions. The subsequent financial crisis and global slowdown created a cash crisis, leading to sale of assets, as in the case of Wockhardt. How can the government protect the industry from excessive ambition? What is more, the Indian takeover initiative is still on with Sun Pharma locked in a hostile takeover battle for Israel’s Taro. Hardly the moment for the government to say, we don’t like takeovers.</font> </p><p align="justify"><font >The Indian pharmaceutical industry certainly needs to do better, earn a higher margin which enables the best players to invest more in research to discover new molecules. Western firms do this by selling medicines generally at a high price and earning massively through their blockbuster patents. But Indian firms have excelled in high quality with low cost in the intensely competitive generics space. So, there is a chicken and egg dilemma here — you can’t invest heavily in R&D unless you have blockbusters, which you don’t get unless you invest heavily in R&D. There is a way out. What you cannot earn through high price, you can do partially by expanding volumes. Both public and private healthcare expenditure in India needs to go up enormously, thus giving Indian companies the necessary volumes. The government can help by sharply increasing public spending on healthcare. Plus, the Indian market is full of substandard medicines produced by small-scale units, which survive because of state government patronage and heavily discounted sales through chemists. The government can and should crack down on substandard drugs. This will mean higher sales for large, quality producers and so, more resources for research.</font> </p><p align="justify"><font ><br /> <br /> <br /> </font> </p> </font> </td> </tr> <tr> <td> </td> </tr> <tr> <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;"> <form><input type="button" value=" Print this page " onclick="window.print();return false;"/></form> </td> </tr> </table></body> </html>' } $reasonPhrase = 'OK'header - [internal], line ?? Cake\Http\ResponseEmitter::emitStatusLine() - CORE/src/Http/ResponseEmitter.php, line 148 Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 54 Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141 [main] - ROOT/webroot/index.php, line 39
Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 181]Notice (8): Undefined variable: urlPrefix [APP/Template/Layout/printlayout.ctp, line 8]Code Context$value
), $first);
$first = false;
$response = object(Cake\Http\Response) { 'status' => (int) 200, 'contentType' => 'text/html', 'headers' => [ 'Content-Type' => [ [maximum depth reached] ] ], 'file' => null, 'fileRange' => [], 'cookies' => object(Cake\Http\Cookie\CookieCollection) {}, 'cacheDirectives' => [], 'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd"> <html xmlns="http://www.w3.org/1999/xhtml"> <head> <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr6824c0b99a162-trace').style.display = (document.getElementById('cakeErr6824c0b99a162-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr6824c0b99a162-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr6824c0b99a162-code').style.display = (document.getElementById('cakeErr6824c0b99a162-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr6824c0b99a162-context').style.display = (document.getElementById('cakeErr6824c0b99a162-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr6824c0b99a162-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700"><</span><span style="color: #0000BB">head</span><span style="color: #007700">> </span></span></code> <span class="code-highlight"><code><span style="color: #000000"> <link rel="canonical" href="<span style="color: #0000BB"><?php </span><span style="color: #007700">echo </span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">); </span><span style="color: #0000BB">?><?php </span><span style="color: #007700">echo </span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?><?php </span><span style="color: #007700">echo </span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-></span><span style="color: #0000BB">category</span><span style="color: #007700">-></span><span style="color: #0000BB">slug</span><span style="color: #007700">; </span><span style="color: #0000BB">?></span>/<span style="color: #0000BB"><?php </span><span style="color: #007700">echo </span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-></span><span style="color: #0000BB">seo_url</span><span style="color: #007700">; </span><span style="color: #0000BB">?></span>.html"/> </span></code></span> <code><span style="color: #000000"><span style="color: #0000BB"> </span><span style="color: #007700"><</span><span style="color: #0000BB">meta http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type" </span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html; charset=utf-8"</span><span style="color: #007700">/> </span></span></code></pre><pre id="cakeErr6824c0b99a162-context" class="cake-context" style="display: none;">$viewFile = '/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp' $dataForView = [ 'article_current' => object(App\Model\Entity\Article) { 'id' => (int) 296, 'title' => 'Not the right medicine', 'subheading' => '', 'description' => '<p align="justify"> <font face="arial,helvetica,sans-serif" size="3"><em>Govt can help by raising public spending on healthcare</em></font> </p> <p align="justify"> <font face="arial,helvetica,sans-serif" size="3">The Indian Pharmaceutical Alliance, which represents a large section of the country&rsquo;s pharmaceutical companies, has taken the rather unusual step of asking the government to come to the aid of the industry, which has seen a string of foreign acquisitions of Indian players. None of these acquisitions is hostile. So, where does the government come in, particularly when there is no security issue at stake? It is also quite clear that some of these deals, like the most celebrated one of Ranbaxy going to its Japanese acquirer Daiichi Sankyo, have been very attractively priced. So, the industry has been doing quite well and managements have been able to exit at a premium. If the industry were in trouble and, therefore, needing government assistance, the scenario would have been different.</font> </p> <p align="justify"> <font face="arial,helvetica,sans-serif" size="3">Big global pharmaceutical firms seeking to buy into prominent Indian generic players is, in fact, a vindication of the Indian pharmaceutical story which began with the decision by Indira Gandhi to rein in the cost of medicines and allow process and not product patents. This policy environment and Indian expertise in chemistry led to the emergence of India as a prominent global player in generic drugs. As the patent pipeline of global firms has thinned out in recent years, they have realised the need to acquire a generics play and come shopping to India. Leading Indian players, for their part, have realised the importance of original drug discovery and firms like Ranbaxy and Dr Reddy&rsquo;s have since the early 90s concentrated heavily on it. Over the years, all important Indian players have seen the need to acquire a global footprint in terms of distribution and front offices and have gone shopping round the world. Things came to a head during the boom and easy money period earlier in this decade, leading to rather bold leveraged acquisitions. The subsequent financial crisis and global slowdown created a cash crisis, leading to sale of assets, as in the case of Wockhardt. How can the government protect the industry from excessive ambition? What is more, the Indian takeover initiative is still on with Sun Pharma locked in a hostile takeover battle for Israel&rsquo;s Taro. Hardly the moment for the government to say, we don&rsquo;t like takeovers.</font> </p> <p align="justify"> <font face="arial,helvetica,sans-serif" size="3">The Indian pharmaceutical industry certainly needs to do better, earn a higher margin which enables the best players to invest more in research to discover new molecules. Western firms do this by selling medicines generally at a high price and earning massively through their blockbuster patents. But Indian firms have excelled in high quality with low cost in the intensely competitive generics space. So, there is a chicken and egg dilemma here &mdash; you can&rsquo;t invest heavily in R&amp;D unless you have blockbusters, which you don&rsquo;t get unless you invest heavily in R&amp;D. There is a way out. What you cannot earn through high price, you can do partially by expanding volumes. Both public and private healthcare expenditure in India needs to go up enormously, thus giving Indian companies the necessary volumes. The government can help by sharply increasing public spending on healthcare. Plus, the Indian market is full of substandard medicines produced by small-scale units, which survive because of state government patronage and heavily discounted sales through chemists. The government can and should crack down on substandard drugs. This will mean higher sales for large, quality producers and so, more resources for research.</font> </p> <p align="justify"> <font face="arial,helvetica,sans-serif" size="3"><br /> &nbsp;<br /> &nbsp;<br /> &nbsp;</font> </p> ', 'credit_writer' => 'The Business Standard, 3 November, 2009, http://www.business-standard.com/india/news/notright-medicine/375100/', 'article_img' => '', 'article_img_thumb' => '', 'status' => (int) 1, 'show_on_home' => (int) 1, 'lang' => 'EN', 'category_id' => (int) 16, 'tag_keyword' => '', 'seo_url' => 'not-the-right-medicine-363', 'meta_title' => null, 'meta_keywords' => null, 'meta_description' => null, 'noindex' => (int) 0, 'publish_date' => object(Cake\I18n\FrozenDate) {}, 'most_visit_section_id' => null, 'article_big_img' => null, 'liveid' => (int) 363, 'created' => object(Cake\I18n\FrozenTime) {}, 'modified' => object(Cake\I18n\FrozenTime) {}, 'edate' => '', 'tags' => [[maximum depth reached]], 'category' => object(App\Model\Entity\Category) {}, '[new]' => false, '[accessible]' => [ [maximum depth reached] ], '[dirty]' => [[maximum depth reached]], '[original]' => [[maximum depth reached]], '[virtual]' => [[maximum depth reached]], '[hasErrors]' => false, '[errors]' => [[maximum depth reached]], '[invalid]' => [[maximum depth reached]], '[repository]' => 'Articles' }, 'articleid' => (int) 296, 'metaTitle' => 'LATEST NEWS UPDATES | Not the right medicine', 'metaKeywords' => null, 'metaDesc' => ' Govt can help by raising public spending on healthcare The Indian Pharmaceutical Alliance, which represents a large section of the country&rsquo;s pharmaceutical companies, has taken the rather unusual step of asking the government to come to the aid of the...', 'disp' => '<p align="justify"><font ><em>Govt can help by raising public spending on healthcare</em></font> </p><p align="justify"><font >The Indian Pharmaceutical Alliance, which represents a large section of the country&rsquo;s pharmaceutical companies, has taken the rather unusual step of asking the government to come to the aid of the industry, which has seen a string of foreign acquisitions of Indian players. None of these acquisitions is hostile. So, where does the government come in, particularly when there is no security issue at stake? It is also quite clear that some of these deals, like the most celebrated one of Ranbaxy going to its Japanese acquirer Daiichi Sankyo, have been very attractively priced. So, the industry has been doing quite well and managements have been able to exit at a premium. If the industry were in trouble and, therefore, needing government assistance, the scenario would have been different.</font> </p><p align="justify"><font >Big global pharmaceutical firms seeking to buy into prominent Indian generic players is, in fact, a vindication of the Indian pharmaceutical story which began with the decision by Indira Gandhi to rein in the cost of medicines and allow process and not product patents. This policy environment and Indian expertise in chemistry led to the emergence of India as a prominent global player in generic drugs. As the patent pipeline of global firms has thinned out in recent years, they have realised the need to acquire a generics play and come shopping to India. Leading Indian players, for their part, have realised the importance of original drug discovery and firms like Ranbaxy and Dr Reddy&rsquo;s have since the early 90s concentrated heavily on it. Over the years, all important Indian players have seen the need to acquire a global footprint in terms of distribution and front offices and have gone shopping round the world. Things came to a head during the boom and easy money period earlier in this decade, leading to rather bold leveraged acquisitions. The subsequent financial crisis and global slowdown created a cash crisis, leading to sale of assets, as in the case of Wockhardt. How can the government protect the industry from excessive ambition? What is more, the Indian takeover initiative is still on with Sun Pharma locked in a hostile takeover battle for Israel&rsquo;s Taro. Hardly the moment for the government to say, we don&rsquo;t like takeovers.</font> </p><p align="justify"><font >The Indian pharmaceutical industry certainly needs to do better, earn a higher margin which enables the best players to invest more in research to discover new molecules. Western firms do this by selling medicines generally at a high price and earning massively through their blockbuster patents. But Indian firms have excelled in high quality with low cost in the intensely competitive generics space. So, there is a chicken and egg dilemma here &mdash; you can&rsquo;t invest heavily in R&amp;D unless you have blockbusters, which you don&rsquo;t get unless you invest heavily in R&amp;D. There is a way out. What you cannot earn through high price, you can do partially by expanding volumes. Both public and private healthcare expenditure in India needs to go up enormously, thus giving Indian companies the necessary volumes. The government can help by sharply increasing public spending on healthcare. Plus, the Indian market is full of substandard medicines produced by small-scale units, which survive because of state government patronage and heavily discounted sales through chemists. The government can and should crack down on substandard drugs. This will mean higher sales for large, quality producers and so, more resources for research.</font> </p><p align="justify"><font ><br />&nbsp;<br />&nbsp;<br />&nbsp;</font> </p>', 'lang' => 'English', 'SITE_URL' => 'https://im4change.in/', 'site_title' => 'im4change', 'adminprix' => 'admin' ] $article_current = object(App\Model\Entity\Article) { 'id' => (int) 296, 'title' => 'Not the right medicine', 'subheading' => '', 'description' => '<p align="justify"> <font face="arial,helvetica,sans-serif" size="3"><em>Govt can help by raising public spending on healthcare</em></font> </p> <p align="justify"> <font face="arial,helvetica,sans-serif" size="3">The Indian Pharmaceutical Alliance, which represents a large section of the country&rsquo;s pharmaceutical companies, has taken the rather unusual step of asking the government to come to the aid of the industry, which has seen a string of foreign acquisitions of Indian players. None of these acquisitions is hostile. So, where does the government come in, particularly when there is no security issue at stake? It is also quite clear that some of these deals, like the most celebrated one of Ranbaxy going to its Japanese acquirer Daiichi Sankyo, have been very attractively priced. So, the industry has been doing quite well and managements have been able to exit at a premium. If the industry were in trouble and, therefore, needing government assistance, the scenario would have been different.</font> </p> <p align="justify"> <font face="arial,helvetica,sans-serif" size="3">Big global pharmaceutical firms seeking to buy into prominent Indian generic players is, in fact, a vindication of the Indian pharmaceutical story which began with the decision by Indira Gandhi to rein in the cost of medicines and allow process and not product patents. This policy environment and Indian expertise in chemistry led to the emergence of India as a prominent global player in generic drugs. As the patent pipeline of global firms has thinned out in recent years, they have realised the need to acquire a generics play and come shopping to India. Leading Indian players, for their part, have realised the importance of original drug discovery and firms like Ranbaxy and Dr Reddy&rsquo;s have since the early 90s concentrated heavily on it. Over the years, all important Indian players have seen the need to acquire a global footprint in terms of distribution and front offices and have gone shopping round the world. Things came to a head during the boom and easy money period earlier in this decade, leading to rather bold leveraged acquisitions. The subsequent financial crisis and global slowdown created a cash crisis, leading to sale of assets, as in the case of Wockhardt. How can the government protect the industry from excessive ambition? What is more, the Indian takeover initiative is still on with Sun Pharma locked in a hostile takeover battle for Israel&rsquo;s Taro. Hardly the moment for the government to say, we don&rsquo;t like takeovers.</font> </p> <p align="justify"> <font face="arial,helvetica,sans-serif" size="3">The Indian pharmaceutical industry certainly needs to do better, earn a higher margin which enables the best players to invest more in research to discover new molecules. Western firms do this by selling medicines generally at a high price and earning massively through their blockbuster patents. But Indian firms have excelled in high quality with low cost in the intensely competitive generics space. So, there is a chicken and egg dilemma here &mdash; you can&rsquo;t invest heavily in R&amp;D unless you have blockbusters, which you don&rsquo;t get unless you invest heavily in R&amp;D. There is a way out. What you cannot earn through high price, you can do partially by expanding volumes. Both public and private healthcare expenditure in India needs to go up enormously, thus giving Indian companies the necessary volumes. The government can help by sharply increasing public spending on healthcare. Plus, the Indian market is full of substandard medicines produced by small-scale units, which survive because of state government patronage and heavily discounted sales through chemists. The government can and should crack down on substandard drugs. This will mean higher sales for large, quality producers and so, more resources for research.</font> </p> <p align="justify"> <font face="arial,helvetica,sans-serif" size="3"><br /> &nbsp;<br /> &nbsp;<br /> &nbsp;</font> </p> ', 'credit_writer' => 'The Business Standard, 3 November, 2009, http://www.business-standard.com/india/news/notright-medicine/375100/', 'article_img' => '', 'article_img_thumb' => '', 'status' => (int) 1, 'show_on_home' => (int) 1, 'lang' => 'EN', 'category_id' => (int) 16, 'tag_keyword' => '', 'seo_url' => 'not-the-right-medicine-363', 'meta_title' => null, 'meta_keywords' => null, 'meta_description' => null, 'noindex' => (int) 0, 'publish_date' => object(Cake\I18n\FrozenDate) {}, 'most_visit_section_id' => null, 'article_big_img' => null, 'liveid' => (int) 363, 'created' => object(Cake\I18n\FrozenTime) {}, 'modified' => object(Cake\I18n\FrozenTime) {}, 'edate' => '', 'tags' => [], 'category' => object(App\Model\Entity\Category) {}, '[new]' => false, '[accessible]' => [ '*' => true, 'id' => false ], '[dirty]' => [], '[original]' => [], '[virtual]' => [], '[hasErrors]' => false, '[errors]' => [], '[invalid]' => [], '[repository]' => 'Articles' } $articleid = (int) 296 $metaTitle = 'LATEST NEWS UPDATES | Not the right medicine' $metaKeywords = null $metaDesc = ' Govt can help by raising public spending on healthcare The Indian Pharmaceutical Alliance, which represents a large section of the country&rsquo;s pharmaceutical companies, has taken the rather unusual step of asking the government to come to the aid of the...' $disp = '<p align="justify"><font ><em>Govt can help by raising public spending on healthcare</em></font> </p><p align="justify"><font >The Indian Pharmaceutical Alliance, which represents a large section of the country&rsquo;s pharmaceutical companies, has taken the rather unusual step of asking the government to come to the aid of the industry, which has seen a string of foreign acquisitions of Indian players. None of these acquisitions is hostile. So, where does the government come in, particularly when there is no security issue at stake? It is also quite clear that some of these deals, like the most celebrated one of Ranbaxy going to its Japanese acquirer Daiichi Sankyo, have been very attractively priced. So, the industry has been doing quite well and managements have been able to exit at a premium. If the industry were in trouble and, therefore, needing government assistance, the scenario would have been different.</font> </p><p align="justify"><font >Big global pharmaceutical firms seeking to buy into prominent Indian generic players is, in fact, a vindication of the Indian pharmaceutical story which began with the decision by Indira Gandhi to rein in the cost of medicines and allow process and not product patents. This policy environment and Indian expertise in chemistry led to the emergence of India as a prominent global player in generic drugs. As the patent pipeline of global firms has thinned out in recent years, they have realised the need to acquire a generics play and come shopping to India. Leading Indian players, for their part, have realised the importance of original drug discovery and firms like Ranbaxy and Dr Reddy&rsquo;s have since the early 90s concentrated heavily on it. Over the years, all important Indian players have seen the need to acquire a global footprint in terms of distribution and front offices and have gone shopping round the world. Things came to a head during the boom and easy money period earlier in this decade, leading to rather bold leveraged acquisitions. The subsequent financial crisis and global slowdown created a cash crisis, leading to sale of assets, as in the case of Wockhardt. How can the government protect the industry from excessive ambition? What is more, the Indian takeover initiative is still on with Sun Pharma locked in a hostile takeover battle for Israel&rsquo;s Taro. Hardly the moment for the government to say, we don&rsquo;t like takeovers.</font> </p><p align="justify"><font >The Indian pharmaceutical industry certainly needs to do better, earn a higher margin which enables the best players to invest more in research to discover new molecules. Western firms do this by selling medicines generally at a high price and earning massively through their blockbuster patents. But Indian firms have excelled in high quality with low cost in the intensely competitive generics space. So, there is a chicken and egg dilemma here &mdash; you can&rsquo;t invest heavily in R&amp;D unless you have blockbusters, which you don&rsquo;t get unless you invest heavily in R&amp;D. There is a way out. What you cannot earn through high price, you can do partially by expanding volumes. Both public and private healthcare expenditure in India needs to go up enormously, thus giving Indian companies the necessary volumes. The government can help by sharply increasing public spending on healthcare. Plus, the Indian market is full of substandard medicines produced by small-scale units, which survive because of state government patronage and heavily discounted sales through chemists. The government can and should crack down on substandard drugs. This will mean higher sales for large, quality producers and so, more resources for research.</font> </p><p align="justify"><font ><br />&nbsp;<br />&nbsp;<br />&nbsp;</font> </p>' $lang = 'English' $SITE_URL = 'https://im4change.in/' $site_title = 'im4change' $adminprix = 'admin'</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8 Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413 Cake\View\View::_render() - CORE/src/View/View.php, line 1374 Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927 Cake\View\View::render() - CORE/src/View/View.php, line 885 Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791 Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126 Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94 Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235 Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65 Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162 Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65 Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88 Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65 Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96 Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65 Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/not-the-right-medicine-363.html"/> <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/> <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css" media="all"/> <title>LATEST NEWS UPDATES | Not the right medicine | Im4change.org</title> <meta name="description" content=" Govt can help by raising public spending on healthcare The Indian Pharmaceutical Alliance, which represents a large section of the country’s pharmaceutical companies, has taken the rather unusual step of asking the government to come to the aid of the..."/> <script src="https://im4change.in/js/jquery-1.10.2.js"></script> <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script> <script language="javascript" type="text/javascript"> $(document).ready(function () { var img = $("img")[0]; // Get my img elem var pic_real_width, pic_real_height; $("<img/>") // Make in memory copy of image to avoid css issues .attr("src", $(img).attr("src")) .load(function () { pic_real_width = this.width; // Note: $(this).width() will not pic_real_height = this.height; // work for in memory images. }); }); </script> <style type="text/css"> @media screen { div.divFooter { display: block; } } @media print { .printbutton { display: none !important; } } </style> </head> <body> <table cellpadding="0" cellspacing="0" border="0" width="98%" align="center"> <tr> <td class="top_bg"> <div class="divFooter"> <img src="https://im4change.in/images/logo1.jpg" height="59" border="0" alt="Resource centre on India's rural distress" style="padding-top:14px;"/> </div> </td> </tr> <tr> <td id="topspace"> </td> </tr> <tr id="topspace"> <td> </td> </tr> <tr> <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton"> <form><input type="button" value=" Print this page " onclick="window.print();return false;"/></form> </td> </tr> <tr> <td width="100%"> <h1 class="news_headlines" style="font-style:normal"> <strong>Not the right medicine</strong></h1> </td> </tr> <tr> <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3"> <p align="justify"><font ><em>Govt can help by raising public spending on healthcare</em></font> </p><p align="justify"><font >The Indian Pharmaceutical Alliance, which represents a large section of the country’s pharmaceutical companies, has taken the rather unusual step of asking the government to come to the aid of the industry, which has seen a string of foreign acquisitions of Indian players. None of these acquisitions is hostile. So, where does the government come in, particularly when there is no security issue at stake? It is also quite clear that some of these deals, like the most celebrated one of Ranbaxy going to its Japanese acquirer Daiichi Sankyo, have been very attractively priced. So, the industry has been doing quite well and managements have been able to exit at a premium. If the industry were in trouble and, therefore, needing government assistance, the scenario would have been different.</font> </p><p align="justify"><font >Big global pharmaceutical firms seeking to buy into prominent Indian generic players is, in fact, a vindication of the Indian pharmaceutical story which began with the decision by Indira Gandhi to rein in the cost of medicines and allow process and not product patents. This policy environment and Indian expertise in chemistry led to the emergence of India as a prominent global player in generic drugs. As the patent pipeline of global firms has thinned out in recent years, they have realised the need to acquire a generics play and come shopping to India. Leading Indian players, for their part, have realised the importance of original drug discovery and firms like Ranbaxy and Dr Reddy’s have since the early 90s concentrated heavily on it. Over the years, all important Indian players have seen the need to acquire a global footprint in terms of distribution and front offices and have gone shopping round the world. Things came to a head during the boom and easy money period earlier in this decade, leading to rather bold leveraged acquisitions. The subsequent financial crisis and global slowdown created a cash crisis, leading to sale of assets, as in the case of Wockhardt. How can the government protect the industry from excessive ambition? What is more, the Indian takeover initiative is still on with Sun Pharma locked in a hostile takeover battle for Israel’s Taro. Hardly the moment for the government to say, we don’t like takeovers.</font> </p><p align="justify"><font >The Indian pharmaceutical industry certainly needs to do better, earn a higher margin which enables the best players to invest more in research to discover new molecules. Western firms do this by selling medicines generally at a high price and earning massively through their blockbuster patents. But Indian firms have excelled in high quality with low cost in the intensely competitive generics space. So, there is a chicken and egg dilemma here — you can’t invest heavily in R&D unless you have blockbusters, which you don’t get unless you invest heavily in R&D. There is a way out. What you cannot earn through high price, you can do partially by expanding volumes. Both public and private healthcare expenditure in India needs to go up enormously, thus giving Indian companies the necessary volumes. The government can help by sharply increasing public spending on healthcare. Plus, the Indian market is full of substandard medicines produced by small-scale units, which survive because of state government patronage and heavily discounted sales through chemists. The government can and should crack down on substandard drugs. This will mean higher sales for large, quality producers and so, more resources for research.</font> </p><p align="justify"><font ><br /> <br /> <br /> </font> </p> </font> </td> </tr> <tr> <td> </td> </tr> <tr> <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;"> <form><input type="button" value=" Print this page " onclick="window.print();return false;"/></form> </td> </tr> </table></body> </html>' } $cookies = [] $values = [ (int) 0 => 'text/html; charset=UTF-8' ] $name = 'Content-Type' $first = true $value = 'text/html; charset=UTF-8'header - [internal], line ?? Cake\Http\ResponseEmitter::emitHeaders() - CORE/src/Http/ResponseEmitter.php, line 181 Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 55 Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141 [main] - ROOT/webroot/index.php, line 39
<head>
<link rel="canonical" href="<?php echo Configure::read('SITE_URL'); ?><?php echo $urlPrefix;?><?php echo $article_current->category->slug; ?>/<?php echo $article_current->seo_url; ?>.html"/>
<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
$viewFile = '/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp' $dataForView = [ 'article_current' => object(App\Model\Entity\Article) { 'id' => (int) 296, 'title' => 'Not the right medicine', 'subheading' => '', 'description' => '<p align="justify"> <font face="arial,helvetica,sans-serif" size="3"><em>Govt can help by raising public spending on healthcare</em></font> </p> <p align="justify"> <font face="arial,helvetica,sans-serif" size="3">The Indian Pharmaceutical Alliance, which represents a large section of the country’s pharmaceutical companies, has taken the rather unusual step of asking the government to come to the aid of the industry, which has seen a string of foreign acquisitions of Indian players. None of these acquisitions is hostile. So, where does the government come in, particularly when there is no security issue at stake? It is also quite clear that some of these deals, like the most celebrated one of Ranbaxy going to its Japanese acquirer Daiichi Sankyo, have been very attractively priced. So, the industry has been doing quite well and managements have been able to exit at a premium. If the industry were in trouble and, therefore, needing government assistance, the scenario would have been different.</font> </p> <p align="justify"> <font face="arial,helvetica,sans-serif" size="3">Big global pharmaceutical firms seeking to buy into prominent Indian generic players is, in fact, a vindication of the Indian pharmaceutical story which began with the decision by Indira Gandhi to rein in the cost of medicines and allow process and not product patents. This policy environment and Indian expertise in chemistry led to the emergence of India as a prominent global player in generic drugs. As the patent pipeline of global firms has thinned out in recent years, they have realised the need to acquire a generics play and come shopping to India. Leading Indian players, for their part, have realised the importance of original drug discovery and firms like Ranbaxy and Dr Reddy’s have since the early 90s concentrated heavily on it. Over the years, all important Indian players have seen the need to acquire a global footprint in terms of distribution and front offices and have gone shopping round the world. Things came to a head during the boom and easy money period earlier in this decade, leading to rather bold leveraged acquisitions. The subsequent financial crisis and global slowdown created a cash crisis, leading to sale of assets, as in the case of Wockhardt. How can the government protect the industry from excessive ambition? What is more, the Indian takeover initiative is still on with Sun Pharma locked in a hostile takeover battle for Israel’s Taro. Hardly the moment for the government to say, we don’t like takeovers.</font> </p> <p align="justify"> <font face="arial,helvetica,sans-serif" size="3">The Indian pharmaceutical industry certainly needs to do better, earn a higher margin which enables the best players to invest more in research to discover new molecules. Western firms do this by selling medicines generally at a high price and earning massively through their blockbuster patents. But Indian firms have excelled in high quality with low cost in the intensely competitive generics space. So, there is a chicken and egg dilemma here — you can’t invest heavily in R&D unless you have blockbusters, which you don’t get unless you invest heavily in R&D. There is a way out. What you cannot earn through high price, you can do partially by expanding volumes. Both public and private healthcare expenditure in India needs to go up enormously, thus giving Indian companies the necessary volumes. The government can help by sharply increasing public spending on healthcare. Plus, the Indian market is full of substandard medicines produced by small-scale units, which survive because of state government patronage and heavily discounted sales through chemists. The government can and should crack down on substandard drugs. This will mean higher sales for large, quality producers and so, more resources for research.</font> </p> <p align="justify"> <font face="arial,helvetica,sans-serif" size="3"><br /> <br /> <br /> </font> </p> ', 'credit_writer' => 'The Business Standard, 3 November, 2009, http://www.business-standard.com/india/news/notright-medicine/375100/', 'article_img' => '', 'article_img_thumb' => '', 'status' => (int) 1, 'show_on_home' => (int) 1, 'lang' => 'EN', 'category_id' => (int) 16, 'tag_keyword' => '', 'seo_url' => 'not-the-right-medicine-363', 'meta_title' => null, 'meta_keywords' => null, 'meta_description' => null, 'noindex' => (int) 0, 'publish_date' => object(Cake\I18n\FrozenDate) {}, 'most_visit_section_id' => null, 'article_big_img' => null, 'liveid' => (int) 363, 'created' => object(Cake\I18n\FrozenTime) {}, 'modified' => object(Cake\I18n\FrozenTime) {}, 'edate' => '', 'tags' => [[maximum depth reached]], 'category' => object(App\Model\Entity\Category) {}, '[new]' => false, '[accessible]' => [ [maximum depth reached] ], '[dirty]' => [[maximum depth reached]], '[original]' => [[maximum depth reached]], '[virtual]' => [[maximum depth reached]], '[hasErrors]' => false, '[errors]' => [[maximum depth reached]], '[invalid]' => [[maximum depth reached]], '[repository]' => 'Articles' }, 'articleid' => (int) 296, 'metaTitle' => 'LATEST NEWS UPDATES | Not the right medicine', 'metaKeywords' => null, 'metaDesc' => ' Govt can help by raising public spending on healthcare The Indian Pharmaceutical Alliance, which represents a large section of the country’s pharmaceutical companies, has taken the rather unusual step of asking the government to come to the aid of the...', 'disp' => '<p align="justify"><font ><em>Govt can help by raising public spending on healthcare</em></font> </p><p align="justify"><font >The Indian Pharmaceutical Alliance, which represents a large section of the country’s pharmaceutical companies, has taken the rather unusual step of asking the government to come to the aid of the industry, which has seen a string of foreign acquisitions of Indian players. None of these acquisitions is hostile. So, where does the government come in, particularly when there is no security issue at stake? It is also quite clear that some of these deals, like the most celebrated one of Ranbaxy going to its Japanese acquirer Daiichi Sankyo, have been very attractively priced. So, the industry has been doing quite well and managements have been able to exit at a premium. If the industry were in trouble and, therefore, needing government assistance, the scenario would have been different.</font> </p><p align="justify"><font >Big global pharmaceutical firms seeking to buy into prominent Indian generic players is, in fact, a vindication of the Indian pharmaceutical story which began with the decision by Indira Gandhi to rein in the cost of medicines and allow process and not product patents. This policy environment and Indian expertise in chemistry led to the emergence of India as a prominent global player in generic drugs. As the patent pipeline of global firms has thinned out in recent years, they have realised the need to acquire a generics play and come shopping to India. Leading Indian players, for their part, have realised the importance of original drug discovery and firms like Ranbaxy and Dr Reddy’s have since the early 90s concentrated heavily on it. Over the years, all important Indian players have seen the need to acquire a global footprint in terms of distribution and front offices and have gone shopping round the world. Things came to a head during the boom and easy money period earlier in this decade, leading to rather bold leveraged acquisitions. The subsequent financial crisis and global slowdown created a cash crisis, leading to sale of assets, as in the case of Wockhardt. How can the government protect the industry from excessive ambition? What is more, the Indian takeover initiative is still on with Sun Pharma locked in a hostile takeover battle for Israel’s Taro. Hardly the moment for the government to say, we don’t like takeovers.</font> </p><p align="justify"><font >The Indian pharmaceutical industry certainly needs to do better, earn a higher margin which enables the best players to invest more in research to discover new molecules. Western firms do this by selling medicines generally at a high price and earning massively through their blockbuster patents. But Indian firms have excelled in high quality with low cost in the intensely competitive generics space. So, there is a chicken and egg dilemma here — you can’t invest heavily in R&D unless you have blockbusters, which you don’t get unless you invest heavily in R&D. There is a way out. What you cannot earn through high price, you can do partially by expanding volumes. Both public and private healthcare expenditure in India needs to go up enormously, thus giving Indian companies the necessary volumes. The government can help by sharply increasing public spending on healthcare. Plus, the Indian market is full of substandard medicines produced by small-scale units, which survive because of state government patronage and heavily discounted sales through chemists. The government can and should crack down on substandard drugs. This will mean higher sales for large, quality producers and so, more resources for research.</font> </p><p align="justify"><font ><br /> <br /> <br /> </font> </p>', 'lang' => 'English', 'SITE_URL' => 'https://im4change.in/', 'site_title' => 'im4change', 'adminprix' => 'admin' ] $article_current = object(App\Model\Entity\Article) { 'id' => (int) 296, 'title' => 'Not the right medicine', 'subheading' => '', 'description' => '<p align="justify"> <font face="arial,helvetica,sans-serif" size="3"><em>Govt can help by raising public spending on healthcare</em></font> </p> <p align="justify"> <font face="arial,helvetica,sans-serif" size="3">The Indian Pharmaceutical Alliance, which represents a large section of the country’s pharmaceutical companies, has taken the rather unusual step of asking the government to come to the aid of the industry, which has seen a string of foreign acquisitions of Indian players. None of these acquisitions is hostile. So, where does the government come in, particularly when there is no security issue at stake? It is also quite clear that some of these deals, like the most celebrated one of Ranbaxy going to its Japanese acquirer Daiichi Sankyo, have been very attractively priced. So, the industry has been doing quite well and managements have been able to exit at a premium. If the industry were in trouble and, therefore, needing government assistance, the scenario would have been different.</font> </p> <p align="justify"> <font face="arial,helvetica,sans-serif" size="3">Big global pharmaceutical firms seeking to buy into prominent Indian generic players is, in fact, a vindication of the Indian pharmaceutical story which began with the decision by Indira Gandhi to rein in the cost of medicines and allow process and not product patents. This policy environment and Indian expertise in chemistry led to the emergence of India as a prominent global player in generic drugs. As the patent pipeline of global firms has thinned out in recent years, they have realised the need to acquire a generics play and come shopping to India. Leading Indian players, for their part, have realised the importance of original drug discovery and firms like Ranbaxy and Dr Reddy’s have since the early 90s concentrated heavily on it. Over the years, all important Indian players have seen the need to acquire a global footprint in terms of distribution and front offices and have gone shopping round the world. Things came to a head during the boom and easy money period earlier in this decade, leading to rather bold leveraged acquisitions. The subsequent financial crisis and global slowdown created a cash crisis, leading to sale of assets, as in the case of Wockhardt. How can the government protect the industry from excessive ambition? What is more, the Indian takeover initiative is still on with Sun Pharma locked in a hostile takeover battle for Israel’s Taro. Hardly the moment for the government to say, we don’t like takeovers.</font> </p> <p align="justify"> <font face="arial,helvetica,sans-serif" size="3">The Indian pharmaceutical industry certainly needs to do better, earn a higher margin which enables the best players to invest more in research to discover new molecules. Western firms do this by selling medicines generally at a high price and earning massively through their blockbuster patents. But Indian firms have excelled in high quality with low cost in the intensely competitive generics space. So, there is a chicken and egg dilemma here — you can’t invest heavily in R&D unless you have blockbusters, which you don’t get unless you invest heavily in R&D. There is a way out. What you cannot earn through high price, you can do partially by expanding volumes. Both public and private healthcare expenditure in India needs to go up enormously, thus giving Indian companies the necessary volumes. The government can help by sharply increasing public spending on healthcare. Plus, the Indian market is full of substandard medicines produced by small-scale units, which survive because of state government patronage and heavily discounted sales through chemists. The government can and should crack down on substandard drugs. This will mean higher sales for large, quality producers and so, more resources for research.</font> </p> <p align="justify"> <font face="arial,helvetica,sans-serif" size="3"><br /> <br /> <br /> </font> </p> ', 'credit_writer' => 'The Business Standard, 3 November, 2009, http://www.business-standard.com/india/news/notright-medicine/375100/', 'article_img' => '', 'article_img_thumb' => '', 'status' => (int) 1, 'show_on_home' => (int) 1, 'lang' => 'EN', 'category_id' => (int) 16, 'tag_keyword' => '', 'seo_url' => 'not-the-right-medicine-363', 'meta_title' => null, 'meta_keywords' => null, 'meta_description' => null, 'noindex' => (int) 0, 'publish_date' => object(Cake\I18n\FrozenDate) {}, 'most_visit_section_id' => null, 'article_big_img' => null, 'liveid' => (int) 363, 'created' => object(Cake\I18n\FrozenTime) {}, 'modified' => object(Cake\I18n\FrozenTime) {}, 'edate' => '', 'tags' => [], 'category' => object(App\Model\Entity\Category) {}, '[new]' => false, '[accessible]' => [ '*' => true, 'id' => false ], '[dirty]' => [], '[original]' => [], '[virtual]' => [], '[hasErrors]' => false, '[errors]' => [], '[invalid]' => [], '[repository]' => 'Articles' } $articleid = (int) 296 $metaTitle = 'LATEST NEWS UPDATES | Not the right medicine' $metaKeywords = null $metaDesc = ' Govt can help by raising public spending on healthcare The Indian Pharmaceutical Alliance, which represents a large section of the country’s pharmaceutical companies, has taken the rather unusual step of asking the government to come to the aid of the...' $disp = '<p align="justify"><font ><em>Govt can help by raising public spending on healthcare</em></font> </p><p align="justify"><font >The Indian Pharmaceutical Alliance, which represents a large section of the country’s pharmaceutical companies, has taken the rather unusual step of asking the government to come to the aid of the industry, which has seen a string of foreign acquisitions of Indian players. None of these acquisitions is hostile. So, where does the government come in, particularly when there is no security issue at stake? It is also quite clear that some of these deals, like the most celebrated one of Ranbaxy going to its Japanese acquirer Daiichi Sankyo, have been very attractively priced. So, the industry has been doing quite well and managements have been able to exit at a premium. If the industry were in trouble and, therefore, needing government assistance, the scenario would have been different.</font> </p><p align="justify"><font >Big global pharmaceutical firms seeking to buy into prominent Indian generic players is, in fact, a vindication of the Indian pharmaceutical story which began with the decision by Indira Gandhi to rein in the cost of medicines and allow process and not product patents. This policy environment and Indian expertise in chemistry led to the emergence of India as a prominent global player in generic drugs. As the patent pipeline of global firms has thinned out in recent years, they have realised the need to acquire a generics play and come shopping to India. Leading Indian players, for their part, have realised the importance of original drug discovery and firms like Ranbaxy and Dr Reddy’s have since the early 90s concentrated heavily on it. Over the years, all important Indian players have seen the need to acquire a global footprint in terms of distribution and front offices and have gone shopping round the world. Things came to a head during the boom and easy money period earlier in this decade, leading to rather bold leveraged acquisitions. The subsequent financial crisis and global slowdown created a cash crisis, leading to sale of assets, as in the case of Wockhardt. How can the government protect the industry from excessive ambition? What is more, the Indian takeover initiative is still on with Sun Pharma locked in a hostile takeover battle for Israel’s Taro. Hardly the moment for the government to say, we don’t like takeovers.</font> </p><p align="justify"><font >The Indian pharmaceutical industry certainly needs to do better, earn a higher margin which enables the best players to invest more in research to discover new molecules. Western firms do this by selling medicines generally at a high price and earning massively through their blockbuster patents. But Indian firms have excelled in high quality with low cost in the intensely competitive generics space. So, there is a chicken and egg dilemma here — you can’t invest heavily in R&D unless you have blockbusters, which you don’t get unless you invest heavily in R&D. There is a way out. What you cannot earn through high price, you can do partially by expanding volumes. Both public and private healthcare expenditure in India needs to go up enormously, thus giving Indian companies the necessary volumes. The government can help by sharply increasing public spending on healthcare. Plus, the Indian market is full of substandard medicines produced by small-scale units, which survive because of state government patronage and heavily discounted sales through chemists. The government can and should crack down on substandard drugs. This will mean higher sales for large, quality producers and so, more resources for research.</font> </p><p align="justify"><font ><br /> <br /> <br /> </font> </p>' $lang = 'English' $SITE_URL = 'https://im4change.in/' $site_title = 'im4change' $adminprix = 'admin'
include - APP/Template/Layout/printlayout.ctp, line 8 Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413 Cake\View\View::_render() - CORE/src/View/View.php, line 1374 Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927 Cake\View\View::render() - CORE/src/View/View.php, line 885 Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791 Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126 Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94 Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235 Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65 Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162 Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65 Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88 Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65 Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96 Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65 Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
![]() |
Not the right medicine |
Govt can help by raising public spending on healthcare The Indian Pharmaceutical Alliance, which represents a large section of the country’s pharmaceutical companies, has taken the rather unusual step of asking the government to come to the aid of the industry, which has seen a string of foreign acquisitions of Indian players. None of these acquisitions is hostile. So, where does the government come in, particularly when there is no security issue at stake? It is also quite clear that some of these deals, like the most celebrated one of Ranbaxy going to its Japanese acquirer Daiichi Sankyo, have been very attractively priced. So, the industry has been doing quite well and managements have been able to exit at a premium. If the industry were in trouble and, therefore, needing government assistance, the scenario would have been different. Big global pharmaceutical firms seeking to buy into prominent Indian generic players is, in fact, a vindication of the Indian pharmaceutical story which began with the decision by Indira Gandhi to rein in the cost of medicines and allow process and not product patents. This policy environment and Indian expertise in chemistry led to the emergence of India as a prominent global player in generic drugs. As the patent pipeline of global firms has thinned out in recent years, they have realised the need to acquire a generics play and come shopping to India. Leading Indian players, for their part, have realised the importance of original drug discovery and firms like Ranbaxy and Dr Reddy’s have since the early 90s concentrated heavily on it. Over the years, all important Indian players have seen the need to acquire a global footprint in terms of distribution and front offices and have gone shopping round the world. Things came to a head during the boom and easy money period earlier in this decade, leading to rather bold leveraged acquisitions. The subsequent financial crisis and global slowdown created a cash crisis, leading to sale of assets, as in the case of Wockhardt. How can the government protect the industry from excessive ambition? What is more, the Indian takeover initiative is still on with Sun Pharma locked in a hostile takeover battle for Israel’s Taro. Hardly the moment for the government to say, we don’t like takeovers. The Indian pharmaceutical industry certainly needs to do better, earn a higher margin which enables the best players to invest more in research to discover new molecules. Western firms do this by selling medicines generally at a high price and earning massively through their blockbuster patents. But Indian firms have excelled in high quality with low cost in the intensely competitive generics space. So, there is a chicken and egg dilemma here — you can’t invest heavily in R&D unless you have blockbusters, which you don’t get unless you invest heavily in R&D. There is a way out. What you cannot earn through high price, you can do partially by expanding volumes. Both public and private healthcare expenditure in India needs to go up enormously, thus giving Indian companies the necessary volumes. The government can help by sharply increasing public spending on healthcare. Plus, the Indian market is full of substandard medicines produced by small-scale units, which survive because of state government patronage and heavily discounted sales through chemists. The government can and should crack down on substandard drugs. This will mean higher sales for large, quality producers and so, more resources for research.
|